Comment on CMS-2026-1255-0001

Summary: Amgen, Inc. supports the proposed rule's goal of improving interoperability and transparency to streamline prior authorization and step therapy processes. However, the company urges CMS to implement strong patient protections, such as exemptions for stabilized patients and clinically appropriate lookback periods, to ensure these technological improvements do not delay access to medically necessary treatments.